RSS

CAPSTONE-2 study

Roche has revealed the results of its Phase III CAPSTONE-2 study in which its investigational oral, single-dose antiviral, baloxavir marboxil, has shown superior efficacy in the primary endpoint of time to improvement of flu symptoms versus placebo. more

News